ForesightBriefs · November 2026Health & Life Sciences Brief Sign in

Amsterdam Forum Foresight · Health & Life Sciences BriefNovember 2026 · 4-minute read

What a new medicine can earn is being reset on both sides of the Atlantic.

Three shifts will shape revenue over the next two years. US tariffs bite unless prices track other rich countries, obesity drugs are moving to cheaper channels, and the EU is cutting baseline protection.

The CEO page · three shifts, what they mean, what to decide

01Tariffs

US tariffs on branded medicines are now in force for everyone without a deal.

02Obesity

Some employers are dropping obesity drugs as Medicare buys them at a low price.

03Europe

EU ministers have signed off shorter baseline protection for new medicines.

For subscribers

The full brief, the strategy pack, the watchlist and our scored calls are for subscribers.

See plans Sign in

Plans

Read it yourself, or bring your team.

Founding reader

€290 / year

The full Individual plan at a founding rate, held for as long as you stay subscribed. For the first 100 readers only.

Join the founding list

Individual

€490 / year

The weekly Radar, every monthly Brief with its strategy pack, the watchlists, our scored calls and the full archive. Or €49 a month.

Join the founding list

Company

€7,500 / year

Everything above for up to fifteen readers, plus the quarterly 12–36 month outlook and a 60-minute briefing with your leadership team.

Join the founding list

Prices exclude VAT. The founding rate closes at 100 readers. Independent: no company pays to be covered, and no subscriber shapes the conclusions.

Not ready to subscribe? Join the founding list

Tell us your sector and plan, and we will be in touch.

Already a subscriber? Sign in